AbbVie Inc (ABBV)vsMednax Inc (MD)
ABBV
AbbVie Inc
$230.01
+2.07%
HEALTHCARE · Cap: $391.50B
MD
Mednax Inc
$23.87
+1.07%
HEALTHCARE · Cap: $2.00B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3152% more annual revenue ($62.82B vs $1.93B). MD leads profitability with a 9.0% profit margin vs 5.8%. MD appears more attractively valued with a PEG of 0.24. MD earns a higher WallStSmart Score of 66/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
MD
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$230.01
$83.79 premium
Margin of Safety
+65.0%
Fair Value
$61.27
Current Price
$23.87
$37.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Growing faster than its price suggests
Attractively priced relative to earnings
Earnings expanding 50.0% YoY
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
3.9% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : MD
The strongest argument for MD centers on PEG Ratio, P/E Ratio, EPS Growth. PEG of 0.24 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : MD
The primary concerns for MD are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
MD carries more volatility with a beta of 0.70 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MD scores higher overall (66/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Mednax Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?